Alkem Laboratories' Q2 FY 2025-26 Quarterly Results

Result Summary

• Alkem Laboratories Ltd reported a 17.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.7%.
• Its expenses for the quarter were up by 16.7% QoQ and 15.9% YoY.
• The net profit increased 16.6% QoQ and increased 11.0% YoY.
• The earnings per share (EPS) of Alkem Laboratories Ltd stood at 63.99 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Alkem Laboratories Ltd is a leading pharmaceutical company in India, primarily engaged in the development, manufacture, and sale of pharmaceutical products. The company operates in the healthcare sector and is known for its wide range of formulations and active pharmaceutical ingredients (APIs). Alkem Laboratories has a significant presence in both domestic and international markets, with a focus on therapeutic segments including antibiotics, anti-infectives, gastrointestinal, and pain management, among others. The company has been involved in continuous research and development to expand its product portfolio and enhance its market presence. As of the latest available information, there are no specific major developments mentioned that could affect the company's operations or financials.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Alkem Laboratories Ltd reported a total income of ₹4104.68 crores. This reflects a quarter-over-quarter (QoQ) increase of 17.0% compared to the previous quarter (Q1FY26) where the total income was ₹3507.63 crores. Year-over-year (YoY), the total income rose by 15.7% from ₹3549.15 crores in Q2FY25. These figures indicate a substantial rise in the company's revenue generation over the examined periods, showcasing its ability to grow its income base.

Profitability

The company's profit before tax (PBT) for Q2FY26 was ₹895.83 crores, which represents a 16.2% increase QoQ from ₹771.01 crores in Q1FY26. Compared to the same quarter in the previous year (Q2FY25), the PBT increased by 14.8% from ₹780.26 crores. The profit after tax (PAT) for Q2FY26 stood at ₹779.11 crores, a 16.6% rise QoQ and an 11.0% increase YoY from ₹701.96 crores in Q2FY25. The tax expenses for the quarter were ₹116.23 crores, marking a 13.2% QoQ increase and a considerable 48.4% YoY rise from ₹78.30 crores in Q2FY25. Earnings per share (EPS) were ₹63.99, showing a 15.2% QoQ growth and an 11.1% YoY increase from ₹57.60 in Q2FY25. These profitability metrics demonstrate the company's effective cost management and revenue enhancement strategies.

Operating Metrics

Total expenses for Alkem Laboratories in Q2FY26 amounted to ₹3208.85 crores, reflecting a 16.7% increase QoQ from ₹2749.55 crores in Q1FY26 and a 15.9% rise YoY from ₹2768.89 crores in Q2FY25. The company's ability to manage expenses in relation to its revenue growth is critical for maintaining profitability. The noticeable increase in tax expenses YoY suggests changes in tax treatment or an increase in taxable income. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio are not provided in the data, which restricts further analysis of the company's financial health and market valuation. However, the available data highlights significant increases in total income and expenses, indicating growth in operational scale.